MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.28

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.24

Максимум

1.34

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+140% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-27M 76M
Предишно отваряне	1.28
Предишно затваряне	1.28

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.01.2026 г., 21:14 ч. UTC

Значими двигатели на пазара

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6.01.2026 г., 19:23 ч. UTC

Придобивния, сливания и поглъщания

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6.01.2026 г., 17:41 ч. UTC

Значими двигатели на пазара

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6.01.2026 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Advent International Leads InPost Takeover Offer, Sky News Says

6.01.2026 г., 15:37 ч. UTC

Значими двигатели на пазара

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6.01.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record High -- Market Talk

6.01.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6.01.2026 г., 23:19 ч. UTC

Пазарно говорене

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6.01.2026 г., 22:53 ч. UTC

Пазарно говорене

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6.01.2026 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6.01.2026 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.01.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.01.2026 г., 21:12 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

6.01.2026 г., 21:12 ч. UTC

Пазарно говорене

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6.01.2026 г., 20:59 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Deal Could Be Announced Imminently, Sources Say -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6.01.2026 г., 20:01 ч. UTC

Пазарно говорене

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6.01.2026 г., 19:52 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6.01.2026 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6.01.2026 г., 19:08 ч. UTC

Придобивния, сливания и поглъщания

OneStream to Go Private Through $6.4B Hg Acquisition

6.01.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

6.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

6.01.2026 г., 15:57 ч. UTC

Пазарно говорене

Crude Futures Ease Back From Early Gains -- Market Talk

6.01.2026 г., 15:34 ч. UTC

Пазарно говорене

Печалби

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6.01.2026 г., 15:27 ч. UTC

Пазарно говорене

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

140% нагоре

12-месечна прогноза

Среден 3 USD 140%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.